Menu Search
Equities

Acasti Pharma Inc

A1P0:FRA

Acasti Pharma Inc

Actions
  • Price (EUR)2.44
  • Today's Change-0.02 / -0.81%
  • Shares traded1.00
  • 1 Year change+35.56%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Acasti Pharma Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. It is focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using its drug delivery technologies. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of more than 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. Its other pipeline drug candidates: GTX-102 and GTX-101. GTX-102 is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia. GTX-101 is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

  • Revenue in USD (TTM)0.00
  • Net income in USD-11.45m
  • Incorporated2002
  • Employees32.00
  • Location
    Acasti Pharma Inc103 Carnegie Center, Suite 300PRINCETON 08540United StatesUSA
  • Phone+1 (450) 686-4555
  • Fax+1 (450) 686-2505
  • Websitehttps://www.acasti.com/en
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.